In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer
Lin ZP, Al Zouabi NN, Xu ML, Bowen NE, Wu TL, Lavi ES, Huang PH, Zhu YL, Kim B, Ratner ES. In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer. Scientific Reports 2021, 11: 8042. PMID: 33850183, PMCID: PMC8044145, DOI: 10.1038/s41598-021-87325-5.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerSmall molecule inhibitorsPARP inhibitor resistancePARP inhibitorsBRCA mutationsOvarian cancerEOC cellsPoly ADP-ribose polymerase inhibitorsMolecule inhibitorsInhibitor resistanceADP-ribose polymerase inhibitorsTumor-bearing miceNovel small molecule inhibitorPARP inhibitor olaparibDefective homologous recombination (HR) repairEOC xenograftsClinical efficacySurvival timePutative small molecule inhibitorsInhibitor olaparibPolymerase inhibitorsHR repairInhibitorsCancerHomologous recombination repairGene expression of non-homologous end-joining pathways in the prognosis of ovarian cancer
Lavi E, Lin Z, Ratner E. Gene expression of non-homologous end-joining pathways in the prognosis of ovarian cancer. IScience 2023, 26: 107934. PMID: 37810216, PMCID: PMC10558711, DOI: 10.1016/j.isci.2023.107934.Peer-Reviewed Original ResearchOvarian cancer patientsClinical outcomesCancer patientsDisease progressionOvarian cancerFive-year overall survival rateOverall survival rateDeadliest gynecologic malignancyLogistic regression modelsGynecologic malignanciesPatient survivalPrognostic biomarkerSurvival rateSample t-testPatientsT-testCancerProgressionRegression modelsOutcomesExpression profilesGene expressionMalignancyPrognosisRecurrence